← ANALYST RATINGS · TIPRANKS
Voyager Therapeutics (VYGR): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $13.75, the highest $25.00, the lowest $8.00. The average is +623.7% from the last price of $1.90.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +5.3% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Sell | +5.3% | Downgrade | 14.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +5.3% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 | Sell | +5.3% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | +5.3% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | +5.3% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| Unknown Analyst | Wells Fargo | $10.00 | Buy | +426.3% | Reiterated | 02.10.26on TipRanks Oct 10 21:02 | −9.2%next day −0.3% · 5 days −1.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 | Sell | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $25.00 | Buy | +1,215.8% | Reiterated | 21.09.26on TipRanks 13:55 | −1.9%next day +2.0% · 5 days −11.3% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $12.00 | Buy | +531.6% | Reiterated | 12.08.26on TipRanks Aug 13 07:15 | −0.3%next day −0.1% · 5 days +7.0% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $8.00 | Buy | +321.1% | Reiterated | 07.08.26on TipRanks 09:35 | +3.9%next day −3.0% · 5 days −0.4% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 06.08.26on TipRanks Aug 7 04:00 | +1.1%next day +3.9% · 5 days +1.7% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $22.00 | Buy | +1,057.9% | Reiterated | 02.06.26on TipRanks 07:15 | −5.4%next day +1.0% · 5 days −1.5% | ↗ |
| Unknown Analyst | Oppenheimer | $18.00 | Buy | +847.4% | Reiterated | 08.05.26on TipRanks 14:25 | +1.4%next day +1.5% · 5 days −7.2% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $11.00 | Buy | +478.9% | Reiterated | 23.03.26on TipRanks 19:30 | +1.4%next day +2.2% · 5 days −1.1% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 17.03.26on TipRanks 07:25 | −9.5%next day −2.7% · 5 days +2.4% | ↗ |
| Unknown Analyst | Wells Fargo | $10.00 | Buy | +426.3% | Reiterated | 11.03.26on TipRanks 07:00 | −2.9%next day +1.9% · 5 days −20.3% | ↗ |
| Lili (Aurélie) Nsongo★★★★★★★★★★#12236 · hits 10% · avg −32.8% | Leerink Partners | $11.00 | Buy | +478.9% | Reiterated | 15.12.25on TipRanks Dec 16 01:50 | −0.5%next day +1.6% · 5 days −4.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Voyager Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.00 at a price of $2.68 (+459.7%); now: $13.75 at $1.90 (+623.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 10 | 13 | 12 | 10 | 7 |
| Buy | 3 | 2 | 3 | 3 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.42 (from $-0.80 to $-0.28). Last quarter: $-0.40.
Sales
Next quarter’s sales estimate — $6M (from $0M to $15M). Last quarter: $3M.
Best top-analyst consensus in the sector · Healthcare
About Voyager Therapeutics
- CEO: Alfred W. Sandrock Jr.
- Employees: 141
- 75 Sidney Street, Lexington, MA, 02421, US
- www.voyagertherapeutics.com
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 143 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗